NCT06738719View on ClinicalTrials.gov

A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

June 25, 2025

Study Completion Date

April 15, 2026

Conditions
Moderately to Severely Active Rheumatoid Arthritis
Interventions
BIOLOGICAL

CT-P13 SC Auto-Injector

Subcutaneous(SC) Injection

BIOLOGICAL

Placebo Auto-Injector

Subcutaneous(SC) Injection

Trial Locations (1)

02-665

Klinika Reuma Park Sp. z.o.o, Warsaw

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT06738719 - A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter